IP Library › Granted Patent US 12697371
Granted Patent B2
US 12697371 · App. 17/420,974 · Granted Aug 4, 2026

Method for preventing, treating or delaying myocardial damage using neuregulin and composition

Inventor: Mingdong Zhou (New South Wales, AU)
Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
A61K38/1883
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697371
App. No.
17/420,974
Granted
Aug 4, 2026
Kind
B2
Abstract

A method for preventing, treating or delaying myocardial damage in a mammal using neuregulin and a composition. An administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating, or delaying myocardial infarction damage.

Claims (8)

1 . A method for treating, or relieving myocardial injury in a mammal, comprising administering to the mammal an effective amount of neuregulin (NRG) at a dose of 2.5 μg/kg/day to 50 μg/kg/day multiple times a day for consecutive days, and following the administration slowly withdrawing the NRG through daily dose reduction within three weeks, wherein the daily dose is half of the administered dose in the first week; the daily dose is a quarter of the administered dose in the second week; and the daily dose is one eighth of the administered dose in the third week.

2 . The method according to claim 1 , wherein the NRG is NRG-1, NRG-2, NRG-3 or NRG-4.

3 . The method according to claim 1 , wherein the NRG is NRG-1.

4 . The method according to claim 1 , wherein the mammal is human.

5 . A method for treating, or relieving myocardial injury in a mammal, comprising administering to the mammal neuregulin (NRG) at a dose of 2.5 μg/kg/day to 50 μg/kg/day multiple times a day for consecutive days, and following the administration slowly withdrawing the NRG through frequency reduction within three weeks comprising: administering the NRG every other day in the first week; administering the NRG every three days in the second week; and administering the NRG every four days in the third week.

6 . The method according to claim 5 , wherein the NRG is NRG-1, NRG-2, NRG-3 or NRG-4.

7 . The method according to claim 5 , wherein the NRG is NRG-1.

8 . The method according to claim 5 , wherein the mammal is human.